Prostatype Genomics AB (publ) provided sales guidance for the year 2022. Sales in 2022 are estimated to amount to SEK 700,000.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.037 SEK | -9.31% | -19.57% | -61.05% |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-61.05% | 3.73M | |
-16.65% | 8.36B | |
+39.98% | 3.6B | |
-32.00% | 2.87B | |
-7.71% | 2.47B | |
-9.65% | 2.24B | |
-13.29% | 1.81B | |
-19.46% | 1.56B | |
-40.57% | 1.23B | |
+9.70% | 1.13B |
- Stock Market
- Equities
- PROGEN Stock
- News Prostatype Genomics AB
- Prostatype Genomics AB Provides Sales Guidance for the Year 2022